PFM Health Sciences’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-149,734
| Closed | -$9.4M | – | 103 |
|
|
2026
Q1 | $9.4M | Sell |
149,734
-77,623
| -34% | -$5.41M | 0.86% | 39 |
|
|
2025
Q4 | $15.1M | Buy |
+227,357
| New | +$14.7M | 1.5% | 25 |
|
|
2025
Q1 | – | Sell |
-328,763
| Closed | -$25.6M | – | 73 |
|
|
2024
Q4 | $25.6M | Buy |
+328,763
| New | +$24.3M | 1.58% | 20 |
|
|
2024
Q3 | – | Sell |
-231,007
| Closed | -$26.2M | – | 78 |
|
|
2024
Q2 | $26.2M | Buy |
231,007
+75,129
| +48% | +$9.5M | 1.3% | 29 |
|
|
2024
Q1 | $21.6M | Buy |
+155,878
| New | +$19.6M | 1.02% | 34 |
|
|
2023
Q4 | – | Sell |
-318,769
| Closed | -$29.7M | – | 70 |
|
|
2023
Q3 | $29.7M | Sell |
318,769
-55,709
| -15% | -$6.28M | 1.4% | 32 |
|
|
2023
Q2 | $48.1M | Sell |
374,478
-49,338
| -12% | -$5.97M | 1.87% | 20 |
|
|
2023
Q1 | $49.2M | Buy |
423,816
+288,351
| +213% | +$32.3M | 2.17% | 11 |
|
|
2022
Q4 | $15.3M | Buy |
+135,465
| New | +$14.9M | 0.55% | 61 |
|
|
2022
Q2 | – | Sell |
-148,084
| Closed | -$18.9M | – | 81 |
|
|
2022
Q1 | $18.9M | Buy |
148,084
+130,208
| +728% | +$14.2M | 0.71% | 48 |
|
|
2021
Q4 | $2.4M | Sell |
17,876
-52,164
| -74% | -$7.5M | 0.08% | 69 |
|
|
2021
Q3 | $9.58M | Buy |
+70,040
| New | +$8.83M | 0.28% | 64 |
|
|
2021
Q2 | – | Sell |
-225,768
| Closed | -$20.3M | – | 89 |
|
|
2021
Q1 | $20.3M | Buy |
+225,768
| New | +$21.2M | 0.62% | 53 |
|
|
2019
Q4 | – | Sell |
-1,712,968
| Closed | -$63.9M | – | 63 |
|
|
2019
Q3 | $63.9M | Buy |
1,712,968
+66,184
| +4% | +$2.57M | 1.89% | 17 |
|
|
2019
Q2 | $61.7M | Buy |
+1,646,784
| New | +$51.8M | 1.17% | 26 |
|
|
2018
Q4 | – | Sell |
-1,221,216
| Closed | -$43.7M | – | 101 |
|
|
2018
Q3 | $43.7M | Buy |
+1,221,216
| New | +$37.9M | 0.64% | 59 |
|
|
2018
Q2 | – | Sell |
-2,056,656
| Closed | -$38.1M | – | 119 |
|
|
2018
Q1 | $38.1M | Buy |
+2,056,656
| New | +$30.4M | 0.77% | 54 |
|
|
2016
Q2 | – | Sell |
-682,140
| Closed | -$11.6M | – | 86 |
|
|
2016
Q1 | $11.6M | Sell |
682,140
-22,012
| -3% | -$368K | 0.36% | 66 |
|
|
2015
Q4 | $14.4M | Buy |
+704,152
| New | +$14.7M | 0.44% | 51 |
|
Other funds holding DXCM
PFM Health Sciences's DXCM Position: Q2 2026 in Review
PFM Health Sciences sold out of DexCom (DXCM) in Q2 2026, closing a stake of 149,734 shares — an estimated $9.4M sold.
PFM Health Sciences first reported a position in DXCM in Q4 2015 and held it in 19 quarters. The position peaked at $63.9M in Q3 2019. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- PFM Health Sciences reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
- PFM Health Sciences sold 149,734 DexCom shares in Q2 2026, an estimated $9.4M.
- PFM Health Sciences first reported a position in DexCom in Q4 2015 and held it in 19 quarters.
- PFM Health Sciences's DexCom position peaked at $63.9M in Q3 2019.
- 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.